[go: up one dir, main page]

WO1998018498A3 - Improvements in or relating to diagnostic/therapeutic agents - Google Patents

Improvements in or relating to diagnostic/therapeutic agents Download PDF

Info

Publication number
WO1998018498A3
WO1998018498A3 PCT/GB1997/002958 GB9702958W WO9818498A3 WO 1998018498 A3 WO1998018498 A3 WO 1998018498A3 GB 9702958 W GB9702958 W GB 9702958W WO 9818498 A3 WO9818498 A3 WO 9818498A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnostic
relating
therapeutic agents
reporter
gas
Prior art date
Application number
PCT/GB1997/002958
Other languages
French (fr)
Other versions
WO1998018498A2 (en
Inventor
Jo Klaveness
Pal Rongved
Anders Hoegset
Helge Tolleshaug
Aslak Godal
Alan Cuthbertson
Dagfinn Loevhaug
Magne Solbakken
Original Assignee
Marsden John Christopher
Nycomed Imaging As
Jo Klaveness
Pal Rongved
Hogset Anders
Helge Tolleshaug
Aslak Godal
Alan Cuthbertson
Lovhaug Dagfinn
Magne Solbakken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622367.2A external-priority patent/GB9622367D0/en
Priority claimed from GBGB9622366.4A external-priority patent/GB9622366D0/en
Priority claimed from GBGB9622364.9A external-priority patent/GB9622364D0/en
Priority claimed from GBGB9700698.5A external-priority patent/GB9700698D0/en
Priority claimed from GBGB9700699.3A external-priority patent/GB9700699D0/en
Priority claimed from GBGB9708265.5A external-priority patent/GB9708265D0/en
Priority claimed from GBGB9711844.2A external-priority patent/GB9711844D0/en
Priority claimed from GBGB9711842.6A external-priority patent/GB9711842D0/en
Priority to JP10520191A priority Critical patent/JP2001502719A/en
Priority to EP97910518A priority patent/EP0963209A2/en
Priority to AU47870/97A priority patent/AU4787097A/en
Application filed by Marsden John Christopher, Nycomed Imaging As, Jo Klaveness, Pal Rongved, Hogset Anders, Helge Tolleshaug, Aslak Godal, Alan Cuthbertson, Lovhaug Dagfinn, Magne Solbakken filed Critical Marsden John Christopher
Publication of WO1998018498A2 publication Critical patent/WO1998018498A2/en
Publication of WO1998018498A3 publication Critical patent/WO1998018498A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generated material, in which the reporter is coupled or linked to one or more non-bioactive vectors.
PCT/GB1997/002958 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents WO1998018498A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU47870/97A AU4787097A (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
EP97910518A EP0963209A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
JP10520191A JP2001502719A (en) 1996-10-28 1997-10-28 Improved diagnostic / therapeutic agents

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
GBGB9622367.2A GB9622367D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GB9622366.4 1996-10-28
GBGB9622364.9A GB9622364D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GB9622364.9 1996-10-28
GB9622367.2 1996-10-28
GBGB9622366.4A GB9622366D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GB9700699.3 1997-01-15
GBGB9700698.5A GB9700698D0 (en) 1997-01-15 1997-01-15 Improvements in or relating to diagnostic/therapeutics agents
GBGB9700699.3A GB9700699D0 (en) 1997-01-15 1997-01-15 Improvements in or relating to diagnostic/therapeutic agents
GB9700698.5 1997-01-15
GB9708265.5 1997-04-24
GBGB9708265.5A GB9708265D0 (en) 1997-04-24 1997-04-24 Contrast agents
US4926597P 1997-06-06 1997-06-06
US4926497P 1997-06-06 1997-06-06
US4926797P 1997-06-06 1997-06-06
GBGB9711844.2A GB9711844D0 (en) 1997-06-06 1997-06-06 Improvements in or relating to diagnostic/therapeutic agents
GB9711842.6 1997-06-06
GBGB9711842.6A GB9711842D0 (en) 1997-06-06 1997-06-06 Improvements in or relating to diagnostic/therapeutic agents
GB9711844.2 1997-06-06

Publications (2)

Publication Number Publication Date
WO1998018498A2 WO1998018498A2 (en) 1998-05-07
WO1998018498A3 true WO1998018498A3 (en) 1998-07-16

Family

ID=27581684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002958 WO1998018498A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents

Country Status (2)

Country Link
EP (1) EP0963209A2 (en)
WO (1) WO1998018498A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884407B1 (en) 1996-09-11 2005-04-26 Bristol-Myers Squibb Pharma Company Methods for diagnostic imaging involving the use of a contrast agent and a coronary vasodilator
US6998107B2 (en) 1991-04-05 2006-02-14 Bristol-Myers Squibb Pharma Comapany Composition comprising low density microspheres
US7078015B2 (en) 1989-12-22 2006-07-18 Imarx Therapeutics, Inc. Ultrasound imaging and treatment
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7329402B2 (en) 1995-06-07 2008-02-12 Imarx Pharmaceutical Corp. Methods of imaging and treatment
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
DE69737915T2 (en) * 1996-09-11 2008-03-13 Bristol-Myers Squibb Medical Imaging, Inc. Method of diagnostic imaging of the kidney region using a contrast agent and a vasodilator
JP2001520207A (en) 1997-10-21 2001-10-30 ニユコメド・イメージング・アクシエセルカペト Ultrasound imaging with contrast agents and vasodilators targeted at microvessels
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
GB9808599D0 (en) * 1998-04-22 1998-06-24 Nycomed Imaging As Improvements in or realting to contrast agents
US6548048B1 (en) 1998-04-28 2003-04-15 Amersham Health As Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents
GB9809084D0 (en) * 1998-04-28 1998-06-24 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
CA2337361C (en) * 1998-07-13 2010-11-16 The Board Of Regents Of The University Of Nebraska Targeted site specific drug delivery compositions and method of use
WO2001017566A2 (en) * 1999-09-08 2001-03-15 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin L-selectin contrast agents
EP1289565B1 (en) 2000-06-02 2015-04-22 Bracco Suisse SA Compounds for targeting endothelial cells
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US6984373B2 (en) 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
EP2301587B1 (en) 2002-03-01 2014-06-25 Dyax Corp. KDR and VEGF/KDR binding peptides and their use in diagnosis
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20050214859A1 (en) 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
JP2007510643A (en) * 2003-11-06 2007-04-26 ジーイー・ヘルスケア・アクスイェ・セルスカプ Pharmaceutical compounds
RU2433137C2 (en) 2005-12-09 2011-11-10 Бракко Суис Са Conjugates of phospholipids and direction vector molecules
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
KR20240005184A (en) 2014-12-31 2024-01-11 랜티우스 메디컬 이메징, 인크. Lipid-encapsulated gas microsphere compositions and related methods
CN109641068B (en) 2016-05-04 2022-09-30 蓝瑟斯医学影像公司 Method and device for preparing ultrasonic contrast agent
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4232755A1 (en) * 1992-09-26 1994-03-31 Schering Ag Microparticle preparations made from biodegradable copolymers
WO1994028873A1 (en) * 1993-06-11 1994-12-22 Unger Evan C Novel therapeutic drug delivery systems
WO1995003356A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
WO1995003357A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Biodegradable particles
WO1995007072A2 (en) * 1993-09-09 1995-03-16 Schering Aktiengesellschaft Active principles and gas containing microparticles
WO1995015118A1 (en) * 1993-11-30 1995-06-08 Imarx Pharmaceutical Corp. Gas microspheres for topical and subcutaneous application
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
EP0727225A2 (en) * 1995-02-14 1996-08-21 Sonus Pharmaceuticals, Inc. Compositions and methods for directed ultrasound imaging
WO1996040277A2 (en) * 1995-06-07 1996-12-19 Brown University Research Foundation Spray dried polymeric microparticles containing imaging agents
WO1996041647A1 (en) * 1995-06-08 1996-12-27 Barnes-Jewish Hospital D/B/A Site specific binding system, imaging compositions and methods
WO1998000172A2 (en) * 1996-06-28 1998-01-08 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4232755A1 (en) * 1992-09-26 1994-03-31 Schering Ag Microparticle preparations made from biodegradable copolymers
WO1994028873A1 (en) * 1993-06-11 1994-12-22 Unger Evan C Novel therapeutic drug delivery systems
WO1995003356A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
WO1995003357A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Biodegradable particles
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
WO1995007072A2 (en) * 1993-09-09 1995-03-16 Schering Aktiengesellschaft Active principles and gas containing microparticles
WO1995015118A1 (en) * 1993-11-30 1995-06-08 Imarx Pharmaceutical Corp. Gas microspheres for topical and subcutaneous application
EP0727225A2 (en) * 1995-02-14 1996-08-21 Sonus Pharmaceuticals, Inc. Compositions and methods for directed ultrasound imaging
WO1996040277A2 (en) * 1995-06-07 1996-12-19 Brown University Research Foundation Spray dried polymeric microparticles containing imaging agents
WO1996041647A1 (en) * 1995-06-08 1996-12-27 Barnes-Jewish Hospital D/B/A Site specific binding system, imaging compositions and methods
WO1998000172A2 (en) * 1996-06-28 1998-01-08 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A.L. KLIBANOV ET AL.: "TARGETING OF ULTRASOUND CONTRAST MATERIAL. AN IN VITOR FEASIBILTY STUDY.", ACTA RADIOLOGICA, vol. 38, no. 412, 1997, pages 113-120, XP002063479 *
V.R. MUZYKANTOV: "IMMUNOTARGETING OF STREPTAVIDIN TO THE PULMONARY ENDOTHELIUM", JOURNAL OF NUCLEAR MEDICINE, vol. 35, no. 8, August 1994 (1994-08-01), NEW YORK US, pages 1358 - 1365, XP002063478 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078015B2 (en) 1989-12-22 2006-07-18 Imarx Therapeutics, Inc. Ultrasound imaging and treatment
US7344705B2 (en) 1991-04-05 2008-03-18 Bristol-Myers Squibb Medical Imaging, Inc. Composition comprising low density microspheres
US6998107B2 (en) 1991-04-05 2006-02-14 Bristol-Myers Squibb Pharma Comapany Composition comprising low density microspheres
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US7329402B2 (en) 1995-06-07 2008-02-12 Imarx Pharmaceutical Corp. Methods of imaging and treatment
US6884407B1 (en) 1996-09-11 2005-04-26 Bristol-Myers Squibb Pharma Company Methods for diagnostic imaging involving the use of a contrast agent and a coronary vasodilator
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US9056138B2 (en) 2002-03-01 2015-06-16 Bracco Suisse Sa Multivalent constructs for therapeutic and diagnostic applications
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Also Published As

Publication number Publication date
EP0963209A2 (en) 1999-12-15
WO1998018498A2 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
WO1998018498A3 (en) Improvements in or relating to diagnostic/therapeutic agents
WO1998018495A3 (en) Improvements in or relating to diagnostic/therapeutic agents
WO1998018500A8 (en) Improvements in or relating to diagnostic/therapeutic agents
WO1998018501A3 (en) Improvements in or relating to diagnostic/therapeutic agents
AU4786697A (en) Improvements in or relating to diagnostic/therapeutic agents
GB9516947D0 (en) Modulators of body weight,corresponding nucleic acids and proteins,and diagnostic and therapeutic uses thereof
AU693826B2 (en) Instrument for the penetration of body tissue
AU6765194A (en) Noninvasive ultrasonic liquid level indicator
AU5665496A (en) Ultrasound contrast agents, containing perfluorocarbon in de xtrose-albumin microbubbles
AU4129696A (en) Composition and method for enhancing electrotransport agent delivery
AU4553793A (en) Use of p97 and iron binding proteins as diagnostic and therapeutic agents
CA2137910A1 (en) Use of microcapsules as contrasting agents in colour doppler sonography
WO2001008711A3 (en) Stable microbubbles for the use as an ultrasound contrast agent
AU6124496A (en) Combinations of active fungicidal agents
IT1277313B1 (en) FIXING COMPLEX OF OSCILLATING SUPPORTS FOR THE DRIVER'S CABIN OF TRUCKS.
ITTO940367A0 (en) PREPARATION OF RIGID POLYURETHANE FOAM WITH THE USE OF POLYOLIPOLYESTERS.
AU3329895A (en) Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2000068384A3 (en) NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
JPH10205076A5 (en)
AU5148896A (en) Hydrazonoacetic acid amides and the use thereof as pesticide s
HUP9904595A2 (en) Improvements in or relating to diagnostic/therapeutic agents
AU738966C (en) Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
RU97119518A (en) ANTI-ALLERGIC MEANS "KATYK"
WO1997004811A3 (en) Use of liposomal preparations in indirect mri lymphography
CA2165282A1 (en) Intravaginal delivery system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 520191

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997910518

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997910518

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997910518

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA